Inclusion Criteria:

- Metastatic pancreatic ductal adenocarcinoma

- Measurable disease

- Life expectancy > 12 weeks

- Normal organ and marrow function

- Fasting blood glucose
- Able to swallow pills

Exclusion Criteria:

- Prior chemotherapy or radiotherapy for treatment of pancreatic cancer

- Receiving any other experimental agent

- Known brain metastases

- History of allergic reaction attributed to compounds of similar chemical or biologic
composition to gemcitabine, erlotinib, or OSI-906

- Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative
disease, uncontrolled nausea, vomiting, or diarrhea)

- Use of enzyme-inducing anti-epileptic drugs

- Diabetes mellitus which requires the use of exogenous insulin for glucose control

- Major surgery within 4 weeks of the start of study treatment

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Use of strong or moderate CYP1A2 inhibitors/inducers

- Pregnant or breast feeding

- History of a different malignancy unless disease-free for at least 3 years

- HIV positive